Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4237 | T-Detect™ SARS-CoV-2 Assay Wiki | 1.00 |
drug4070 | Standard Care Wiki | 0.41 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
- Objective: Our study aims to evaluate the effectiveness of the "STOP" (Sevrage Tabagique à l'aide d'Outils dédiés selon la Préférence: Smoking Cessation using preference-based tools) intervention, a preference-based smoking cessation intervention for smokers with low socio-economic position (SEP). - Methods : STOP is a randomised, multi-centre, single blinded, intent-to-treat trial. Participating centres include primary care practices (community, municipal or general health clinics), hospital-based facilities, and healthcare institutions specialised in addiction treatment. Smokers with low SEP will be randomised into either the intervention or control group. Persons randomised to the control group will be accompanied by their health professional according to standard practice. Participants randomised to the intervention group will receive the same smoking cessation advice, drug (varenicline, champix,..) prescription and support as participants in the control group, but they will also have a choice of being given free Nicotine Replacement Therapy (NRT) (transdermal patch, gum, spray, inhaler, sublingual tablets/lozenges) and/or an electronic cigarette + e-liquid on the spot to aid their quit attempt. Follow-up appointments will take place at around 7 to 14 days, 1 month, 3 months and 6 months after inclusion, according to the participant and health professional availability. The main outcome measure of this study will be smoking abstinence at 6 months after inclusion, defined as self-reported abstinence, with a possibility to validate this outcome by measured exhaled carbon monoxide.
Description: Self-reported continuous abstinence for at least 7 days, validated by measured exhaled carbon monoxide, if this measurement is available (depending on the sanitary measures in place due to the ongoing covid-19 pandemic).
Measure: Smoking abstinence at 6 months after inclusion (yes/no) Time: 6 months after inclusionDescription: Self-reported number of days without any puff
Measure: Total number of days of abstinence at 6 months Time: 6 months after inclusionDescription: Self-reported continuous abstinence for at least 7 days, validated by measured exhaled carbon monoxide, if this measurement is available (depending on the sanitary measures in place due to the ongoing covid-19 pandemic)
Measure: Smoking abstinence at 1 and 3 months after inclusion (yes/no) Time: 1 and 3 months after inclusionDescription: Self-reported
Measure: Number of relapses Time: 3 and 6 months after inclusionDescription: Self-reported
Measure: The number of cigarettes smoked per day Time: 6 months after inclusionDescription: Defined as a reduction in consumption by at least 50% in terms of the number of cigarettes smoked per day or the weight of roll-your-own tobacco per day
Measure: Proportion of participants who have significantly reduced daily smoking Time: 6 months after inclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports